Core Viewpoint - Yifang Biopharma has submitted an application for H-share listing on the Hong Kong Stock Exchange, focusing on innovative targeted drugs for major diseases such as cancer and autoimmune diseases [1] Group 1: Company Overview - Yifang Biopharma specializes in the development of innovative targeted drugs, with a product pipeline that includes two marketed products and several candidates in various stages of clinical development [1] - The company's marketed products, Bafetinib and Gsorese, are included in the National Medical Insurance Drug List in China, generating revenue through external licensing [1][2] - As of the first nine months of 2025, the company reported revenue of 30.89 million yuan and a net loss attributable to shareholders of 181 million yuan, with R&D expenses amounting to 190 million yuan [1] Group 2: R&D Focus and Market Potential - Yifang Biopharma is heavily investing in R&D, particularly in new drugs such as D-2570 for psoriasis and D-0502 for breast cancer, while still in the "burning cash" phase [2] - The number of psoriasis patients in China is projected to reach 6.1 million by 2035, with the global psoriasis drug market expected to grow from $23.9 billion in 2024 to $47 billion by 2035 [2] - The company plans to initiate additional clinical trials for D-2570 targeting PsA, SLE, and vitiligo, indicating a broadening of its therapeutic focus [2] Group 3: Pricing and Market Competition - Bafetinib was included in the National Medical Insurance Directory in 2023, leading to a significant price reduction from approximately 6,000 yuan to about 2,800-2,862 yuan per box, a decrease of 52%-53% [3] - The inclusion of innovative drugs in the National Medical Insurance Directory typically results in increased market competition and reduced profit expectations for pharmaceutical companies [3] - Yifang Biopharma faces challenges with its marketed products due to price pressures and intense competition, while over half of the funds raised from its A-share IPO have already been consumed [3][4] Group 4: Financial Performance - Yifang Biopharma's IPO in July 2022 raised approximately 2.084 billion yuan, with a share price of 18.12 yuan [4] - The company has reported cumulative net losses exceeding 1.189 billion yuan from 2022 to September 2025, indicating ongoing financial challenges [4]

在2025年国家基本药品目录调整中，谈判成功率达到88%，较上一年的76%有明显提升，创近七年新 高。与此同时，在新晋"国谈药"中，有111种为5年内新上市品种，50种为1类新药，无论是比例还是数 量也均创下历年新高。 而与此同时，仍有近百种（98种）药品在形式审查阶段，就被"国谈"拒之门外。近六成目录外药品在专 家评审阶段未过评，过评率连续两年不足50%。15种药在过评后最终谈判/竞价失败。 "一进一拒"，从正反两个维度体现了国家医保局价值购买的方向——在基本医保的保障边界内，支持真 创新，支持差异化创新。 部分业界观点认为，这一方面是因为在申报和形式审查环节，药企申报意愿持续提升，对规则的认知也 更加清晰，形式审查通过数量和通过率不断提升；另一方面，也与目录内药品涵盖适应证不断丰富，创 新药市场上同靶点、同机制、同适应证药品竞争激烈，医保基金紧平衡等多重原因下，国家医保局对创 新要求不断拔高有关。 182种药未过评背后："四不改"、价格与价值不匹配 国家基本药品目录谈判走进第八个年头，已形成了一套成熟的谈判流程：药企自主申报，专家综合评 审，价格谈判/竞价，最终公布谈判结果。 在今年"国谈"中，国家医保局 ...

Core Insights - The approval rate for drugs outside the national essential drug list has reached a four-year low during the expert review phase, indicating increasing scrutiny and higher standards for innovation [1][4] - The success rate for negotiations in the upcoming 2025 national essential drug list has improved to 88%, up from 76% the previous year, marking a seven-year high [1] - A total of 114 new drugs will be added to the national essential drug list, including 50 innovative first-class drugs, reflecting a significant increase in both quantity and quality [2][8] Group 1: Approval Rates and Trends - The approval rate for drugs in the expert review phase has declined for two consecutive years, with only 41.48% of drugs passing this stage this year [2][3] - In the past three years, the number of drugs passing the formal review has increased, but the expert review approval rate has decreased from 74.2% to 47.0% [3] - Nearly 60% of drugs outside the essential list failed to pass the expert review, highlighting a trend towards stricter evaluation criteria [1][4] Group 2: Reasons for Non-Approval - Several drugs, including first-class innovative drugs, were not approved due to lack of significant clinical value compared to existing treatments [5][6] - The "Four No Changes" principle (no change in active ingredient, indication, administration route, or clinical value) has been identified as a key reason for low approval rates [6] - High prices and mismatched value with existing treatments have also contributed to the rejection of certain drugs, with examples of significant price discrepancies noted [6] Group 3: Support for True Innovation - The national healthcare authority emphasizes support for "true innovation" and "differentiated innovation," aiming to exclude drugs that do not significantly advance clinical outcomes [5][7] - Successful drugs entering the essential list share common characteristics such as filling therapeutic gaps and offering superior alternatives [7] - The overall speed and quantity of innovative drugs entering the national essential drug list have increased, addressing various medical needs including major diseases and rare conditions [8] Group 4: Value-Based Pricing and Evaluation - The negotiation process for the national essential drug list has evolved to include a more systematic and scientific value assessment, enhancing fairness and rigor in price evaluations [10] - The approach to pricing has shifted to support higher payment thresholds for drugs with greater innovation, reflecting a value-based pricing model [10][11] - The importance of robust clinical evidence in supporting claims of additional benefits for new drugs has been highlighted, particularly in competitive therapeutic areas [11][12]

Michael MENG Daily Spotlight 8 December 2025 (852) 3988 6433 michael.meng@bocigroup.com Index Performance | | Last close | % 1D | % YTD | | --- | --- | --- | --- | | HSI | 26,085 | 0.6 | 30.0 | | HSCEI | 9,198 | 1.0 | 26.2 | | HSCCI | 4,260 | 0.2 | 12.7 | | MSCI HK | 13,724 | (0.4) | 29.9 | | MSCI CHINA | 85 | 0.8 | 31.6 | | FTSE CHINA A50 | 15,237 | 0.6 | 12.8 | | CSI 300 | 4,585 | 0.8 | 16.5 | | TWSE | 27,981 | 0.7 | 21.5 | | SENSEX | 85,265 | 0.2 | 9.1 | | NIKKEI 225 | 50,492 | (1.1) | 26.6 | | KOSPI | 4 ...

Core Insights - Yifang Bio reported a significant increase in revenue for Q3, achieving 11.73 million yuan, a year-on-year increase of 173.86% [1] - For the first three quarters, the company generated a total revenue of 30.89 million yuan, reflecting a year-on-year growth of 61.27% [1] - The company reported a net loss attributable to shareholders of 61.81 million yuan for the reporting period, an improvement from a loss of 91.09 million yuan in the same period last year, reducing the loss by 29.28 million yuan [1] - Year-to-date, the net loss attributable to shareholders reached 181 million yuan, a reduction of 124 million yuan compared to the previous year [1] Revenue and Profit Analysis - The revenue for the reporting period primarily consisted of recognized income from technology licensing and cooperation [1] - R&D expenses decreased by 35.86% year-on-year due to reduced investment related to the clinical trial of Gsorese, which is expected to conclude in 2024 [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 47.30 CNY, reflecting a reasonable market value of 273.54 billion CNY [4][7]. Core Insights - The company has shown a narrowing loss with a significant increase in commercial product sales, leading to a 29% year-on-year revenue growth in the first half of 2025, achieving 0.19 billion CNY. The net profit attributable to the parent company was -1.19 billion CNY, a 44% reduction in loss compared to the previous year [12]. - The company is actively expanding the indications for its approved products, with ongoing clinical trials for both Beifutini and Gexorase, which are expected to enhance their market presence [12]. - The research pipeline is well-structured, with several promising candidates in advanced clinical stages, indicating strong potential for business development opportunities [12]. Financial Forecast and Analysis - The company’s revenue is projected to decline from 186 million CNY in 2023 to 141 million CNY in 2025, before rebounding to 323 million CNY in 2026 and 525 million CNY in 2027, reflecting a growth rate of 129.3% and 62.6% respectively [6][15]. - The net profit attributable to the parent company is expected to improve from -284 million CNY in 2023 to -203 million CNY in 2025, with a further reduction to -94 million CNY by 2027 [6][15]. - The gross margin is forecasted to remain high, around 97.2% in 2025, while the net margin is expected to improve significantly from -144.0% in 2025 to -17.8% in 2027 [6][15].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 47.30 CNY, reflecting a reasonable market value of 273.54 billion CNY [4][7]. Core Views - The company has shown a narrowing loss with a significant increase in commercial product sales, leading to a 29% year-on-year revenue growth in the first half of 2025, achieving 0.19 billion CNY. The net profit attributable to the parent company was -1.19 billion CNY, a 44% reduction in loss compared to the previous year [12]. - The company is actively expanding the indications for its approved products, with ongoing clinical trials for both Beifutini and Gesorex, which are expected to contribute positively to revenue in the coming years [12]. - The research pipeline is well-structured, with several promising candidates in advanced clinical stages, indicating strong potential for business development opportunities [12]. Financial Summary - The company's revenue is projected to decline from 186 million CNY in 2023 to 141 million CNY in 2025, before rebounding to 323 million CNY in 2026 and 525 million CNY in 2027, reflecting a growth rate of 129.3% and 62.6% respectively [6][15]. - The net profit attributable to the parent company is expected to improve from -284 million CNY in 2023 to -203 million CNY in 2025, with a further reduction to -94 million CNY by 2027 [6][15]. - The gross margin is forecasted to remain high, around 97.2% in 2025, while the net margin is expected to improve significantly from -144.0% in 2025 to -17.8% in 2027 [6][15].

Core Viewpoint - The Social Security Fund has significantly increased its holdings in technology stocks, particularly in the fields of biomedicine, computing, and electronics, reflecting a strategic shift towards sectors supported by national policies and economic transformation [2][6]. Investment Trends - As of the end of Q2 2025, the Social Security Fund held shares in 77 companies listed on the Sci-Tech Innovation Board, with a total holding of 337 million shares valued at 15.37 billion yuan. The fund initiated positions in 19 new stocks and increased holdings in 28 stocks [2]. - The fund's investment style is characterized by a cautious approach, focusing on value investment and long-term returns, with a notable increase in allocations to technology innovation companies [2][5]. Sector Focus - The fund's investments are primarily concentrated in four sectors: electronics (20 companies), biomedicine (13 companies), machinery (10 companies), and computing (11 companies) [2]. - Despite the electronics sector being a market leader, the fund's top 20 holdings are more heavily weighted towards biomedicine and power equipment, with 6 stocks in power equipment and 4 in biomedicine [4]. Stock Performance - The fund's largest single stock holding is Transsion Holdings, with 38.26 million shares, followed by Western Superconducting Technologies with 20.58 million shares. The highest holding percentage is in Andar Intelligent, at 11.90% [3]. - In Q2, the fund increased its holdings in Transsion Holdings by 6.37 million shares, marking the largest increase among individual stocks [4]. New Entrants and Growth - In Q2, the fund entered 19 new stocks, acquiring a total of 45.09 million shares, with significant increases in holdings for Yifang Biopharmaceuticals, Jindun Technology, and Xinzhi Software [6]. - The new stocks showed strong performance, with median revenue and net profit growth rates of 25.7% and 28.14%, respectively, outperforming the overall market [6]. Reduction in Holdings - The fund reduced its holdings in 38 Sci-Tech Innovation Board stocks in Q2, with 24 stocks seeing reductions of over 1 million shares. Notable reductions included Medike and Zexin Pharmaceutical, which had previously seen significant price increases [8][9].

Core Viewpoint - The Social Security Fund has significantly increased its holdings in technology stocks, particularly in the fields of biomedicine, computing, and electronics, reflecting a strategic shift towards sectors supported by national policies and economic transformation [2][6]. Group 1: Investment Trends - As of the end of Q2 2025, the Social Security Fund held 77 stocks from the Sci-Tech Innovation Board, with a total holding of 337 million shares valued at 15.37 billion yuan, having newly entered 19 stocks and increased holdings in 28 [2][3]. - The fund's investment is primarily concentrated in four sectors: electronics (20 companies), biomedicine (13 companies), machinery (10 companies), and computing (11 companies) [2][3]. - The fund's investment style is characterized by a cautious approach, focusing on value investment and long-term returns, with a notable increase in allocations to innovative technology companies [2][5]. Group 2: Sector Preferences - The Social Security Fund's top holdings include companies like Transsion Holdings (38.26 million shares) and Western Superconductor (20.58 million shares), with a significant preference for biomedicine and electric power equipment over electronics [3][4]. - In Q2, the fund increased its holdings in the electronics sector, particularly in Transsion Holdings, which saw an increase of 6.37 million shares, marking the largest increase among individual stocks [4][5]. - The fund's new investments in Q2 included 19 stocks, with a total increase of 45.09 million shares, focusing on high-growth sectors such as biomedicine and computing [7][9]. Group 3: Performance Metrics - The newly added stocks by the Social Security Fund showed strong performance, with median revenue growth of 25.7% and net profit growth of 28.14% in the first half of the year, outperforming the overall market [8][9]. - Specific companies like Yifang Biomedicine and Spring Medical have demonstrated significant revenue and profit growth, indicating the fund's focus on firms with improving performance metrics [10]. Group 4: Reduction in Holdings - In Q2, 38 stocks from the Sci-Tech Innovation Board were reduced in holdings by the Social Security Fund, with 24 of these experiencing reductions of over 1 million shares [11][12]. - Notable reductions included companies like Zekang Pharmaceutical and Longxin Technology, which saw significant price increases post-reduction, indicating potential market volatility [12].

Core Insights - The social security fund has newly invested in 19 stocks in the second quarter, focusing on high-performing sectors such as biomedicine, computers, and electronics, which are aligned with national strategic priorities and economic transformation [1][5] Investment Trends - As of the end of the second quarter, the social security fund held 77 stocks in the Sci-Tech Innovation Board, with a total holding of 337 million shares valued at 15.37 billion yuan, having newly entered 19 stocks and increased holdings in 28 stocks [1][2] - The fund's investment style is characterized by a cautious approach, emphasizing value investment and long-term returns, with a notable increase in allocations to technology innovation companies [1][2] Sector Focus - The fund's holdings are primarily concentrated in four sectors: electronics (20 companies), biomedicine (13 companies), machinery (10 companies), and computers (11 companies) [1] - In terms of stock count, the fund's top holdings include 7 stocks with over 10 million shares, with Transsion Holdings (382.64 million shares) leading, followed by Western Superconducting (205.81 million shares) [2] Performance Metrics - The newly added 19 stocks showed median year-on-year growth rates of 25.7% in revenue and 28.14% in net profit, significantly outperforming the overall market [6] - The fund's focus on biomedicine is evident, with 4 new investments in this sector, alongside 2 each in electronics, military, communications, and computers [6] Notable Stock Movements - The fund increased its holdings in several key stocks, including a significant increase of 6.37 million shares in Transsion Holdings, marking the largest single stock increase for the quarter [3][4] - Other notable increases include 5 stocks in the biomedicine sector and 4 in the computer sector, with specific increases exceeding 1 million shares [4][5] Reduction in Holdings - In the second quarter, 38 stocks on the Sci-Tech Innovation Board were reduced in holdings by the social security fund, with 24 of these seeing reductions of over 1 million shares [8] - Some stocks that were reduced have since experienced significant price increases, indicating a potential misalignment in the fund's timing of trades [8]